Studies of RP 59500 in vitro and in a rabbit model of aortic valve endocarditis caused by methicillin-resistant Staphylococcus aureus.
The activity of RP 59500 against methicillin-resistant Staphylococcus aureus was studied in vitro and in a rabbit model of aortic valve endocarditis. Three strains, 67-O, 529, and Du, ranging from relatively resistant to susceptible to RP 59500 in vitro (mean agar dilution MICs of 0.65, 0.21, and 0.12 mg/L respectively) were used to establish endocarditis, which was treated either with RP 59500, 20 mg/kg im four times a day for four days or with vancomycin, 25 mg/kg iv twice a day for four days. RP 59500 was ineffective for the most resistant strain, 67-O. RP 59500 was effective for the intermediately susceptible strain 529, but vancomycin was more effective. RP 59500 was slightly more effective than vancomycin against the most susceptible strain, Du, but the difference was not statistically significant. These results suggest that strains inhibited by RP 59500 at a concentration of greater than or equal to 0.5 mg/L should probably be considered resistant in this model of infection. RP 59500 was effective in vivo against the two susceptible strains, but overall, vancomycin was the more active drug.
Chambers
H F
HF
Department of Medicine, San Francisco General Hospital, CA 94110.
D000818:Animals; D001021:Aortic Valve; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D006349:Heart Valve Diseases / Q000188:drug therapy; D066298:In Vitro Techniques; D008712:Methicillin / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D014640:Vancomycin / Q000494:pharmacology; D014769:Virginiamycin / Q000494:pharmacology* / Q000627:therapeutic use
D004338:Drug Combinations; D014769:Virginiamycin; C062940:quinupristin-dalfopristin; D014640:Vancomycin; D008712:Methicillin